NAMS — NewAmsterdam Pharma Co N.V.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1936258 ·
Last close
$36.11
Market Cap
$4.22B
52W High
$42.21
52W Low
$27.85
ADV30
1,387,499
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 3,040,000 | — | -58,420,000 | -48,441,000 | 732,643,000 | 457,607,000 | 67,421,000 |
| Dec 2025 | 32,000 | — | -65,980,000 | -74,923,000 | 769,284,000 | 490,002,000 | 85,853,000 |
| Sep 2025 | 348,000 | — | -55,143,000 | -72,005,000 | 786,427,000 | 538,407,000 | 58,357,000 |
| Jun 2025 | 19,145,000 | — | -35,635,000 | -17,364,000 | 815,112,000 | 563,864,000 | 36,615,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-147,783,000
Investing CF
$-174,916,000
Financing CF
$29,520,000
CapEx
$-246,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.28
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-762,390,000
Inventory
—
Receivables
$23,152,000
ST Investments
$146,239,000
EBIT TTM
$-225,683,000
Pretax Income TTM
$-203,819,000
Interest Exp TTM
—
Analysts
13
Yahoo Snapshot (yfinance, live)
Total Revenue
$22,565,000
EBITDA
$-214,948,000
Free Cash Flow
$-58,685,248
Enterprise Value
$3,506,994,944
Total Cash
$636,105,024
Total Debt
$23,000
Shares Out
116,903,979
Trailing EPS
$-1.78
Book Value
$5.97
ROE
-29.5%
ROA
-17.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 22,503,000 | -225,683,000 | -203,819,000 | 769,284,000 | 85,853,000 | — | -147,783,000 |
| Dec 2024 | 45,563,000 | -176,289,000 | -241,598,000 | 864,620,000 | 107,120,000 | — | -158,564,000 |
| Dec 2023 | 14,090,000 | -182,967,000 | -176,937,000 | 347,097,000 | 58,704,000 | — | -141,218,000 |
| Dec 2022 | 102,694,000 | -3,557,000 | -22,634,000 | 478,497,000 | 48,431,000 | — | 10,665,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.29
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MANE | Veradermics, Inc | $4.28B | $102.50 | — |
| TVTX | Travere Therapeutics, Inc. | $4.12B | $44.29 | — |
| AMRX | Amneal Pharmaceuticals, Inc. | $4.08B | $12.79 | — |
| INDV | Indivior Pharmaceuticals, Inc. | $4.47B | $37.81 | — |
| GIKLY | Grifols SA | $4.48B | $5.30 | — |
News headlines (Yahoo Finance, 1h cache)
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
2026-05-11 16:37 · Yahoo
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May
2026-05-11 12:41 · Yahoo
Do NewAmsterdam Pharma’s (NAMS) Dilution Plans Reframe Its Path to Funding Ongoing Losses?
2026-05-08 07:19 · Yahoo
NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends
2026-05-08 06:06 · Yahoo
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates
2026-05-07 12:50 · Yahoo
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
2026-05-07 11:00 · Yahoo
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-01 20:57 · Yahoo
A Look At NewAmsterdam Pharma (NAMS) Valuation As Hedge Funds Focus On Obicetrapib’s Phase 3 LDL C Results
2026-04-09 16:16 · Yahoo
NewAmsterdam Pharma Company (NAMS): Huge Upside Potential Grabs Attention of Billionaire Stan Druckenmiller
2026-04-08 20:29 · Yahoo
NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference
2026-04-08 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.